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doi:10.1016/j.jtcvs.2003.11.047TObjectives: The objective of this study was to examine the long-term patient
outcomes of lung transplantation in a single center.
Methods: Between 1983 and 2003, 521 lung transplants were performed in 501
patients. Major indications were cystic fibrosis (n  124), chronic obstructive
pulmonary disease (n  88), alpha-1 antitrypsin deficiency (n  63), pulmonary
fibrosis (n  97), primary pulmonary hypertension (n  35), Eisenmenger syn-
drome (n  21), and miscellaneous end-stage lung diseases (n  93).
Results: The 5-, 10-, and 15-year survivals for all recipients were 55.1% (95%
confidence interval: 5%), 35.3% (6%), and 26.5% (11%), respectively. The
most common causes of death were sepsis and bronchiolitis obliterans syndrome.
Despite an increased postoperative mortality rate, patients with primary pulmonary
hypertension achieved the best long-term survival (10-year survival: 59%). Recip-
ients with cystic fibrosis without Burkholderia cepacia infection achieved signifi-
cantly better long-term survival (10-year survival: 52%) than those with Burkhold-
eria cepacia infection (10-year survival: 15%). The 10-year survival was also
significantly better in recipients with chronic obstructive pulmonary disease (43%)
than in recipients with alpha-1 antitrypsin deficiency (23%). Although the incidence
of bronchiolitis obliterans syndrome was similar between recipients with chronic
obstructive pulmonary disease (39%) and alpha-1 antitrypsin deficiency (46%),
recipients with alpha-1 antitrypsin deficiency died of sepsis more frequently than
recipients with chronic obstructive pulmonary disease (27% vs 6%, respectively; P
 .0003).
Conclusions: Although bronchiolitis obliterans syndrome and sepsis still limit the
durability of the benefit, lung transplantation returns many patients with end-stage
lung disease to active and productive lives. Differences in the complications and
long-term survival show the important contribution of the recipient diagnosis to the
success of lung transplantation.
The first lung transplantation ever reported in a human was performedby Hardy at the University of Mississippi in 1963 for a patient withadvanced stage bronchogenic carcinoma.1 The patient died of renalfailure after 18 days. During the following 20 years, approximately40 clinical lung allotransplants were performed, but only 1 patientwas discharged from the hospital 8 months after the transplant
2procedure. This patient died a short time later of sepsis. In 1983, Patterson and
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versity of Toronto performed the first successful isolated
single-lung transplant procedure, and in 1986 the same
group described the first successful series of en bloc double-
lung transplants.3,4 The technique of en bloc double-lung
transplantation was supplanted by bilateral sequential lung
transplantation at the end of 1989, a procedure that became
the standard and that has undergone minor changes since
then.5
Whereas the first decade of clinical lung transplantation
focused on technical details of the transplant procedure, the
second decade experienced improvements in techniques of
lung preservation and postoperative management. Improve-
ments in early morbidity and mortality have permitted a
progressive extension of the list of indications for lung
transplantation and gradually led to liberalization of the
lung donor-selection criteria with a subsequent increase in
the number of transplants performed each year.
This report reviews the 20-year experience of the To-
ronto Lung Transplant Program with particular emphasis on
long-term outcomes.
Material and Methods
All lung transplants performed at the Toronto General Hospital
between November 1983 and March 2003 were reviewed. In
addition, physicians in our program have performed all pediatric
lung transplants at the Hospital for Sick Children in Toronto since
1996; these patients were also included in the analysis.
Recipient Selection
Recipients were usually selected according to the guidelines out-
lined by the International Society for Heart and Lung Transplan-
tation and the American Thoracic Society.6 However, the process
of selection has gradually evolved over time. The first single-lung
transplant was performed in a patient with pulmonary fibrosis in
1983, the first heart-lung transplant was performed in a patient
with primary pulmonary hypertension in 1985, and the first dou-
ble-lung transplant was performed in a patient with alpha-1 anti-
trypsin deficiency in 1986. Thereafter, the indications for single-
lung transplant were extended to patients with sarcoidosis and
eosinophilic granuloma in 1987, and double-lung transplants have
been performed in patients with cystic fibrosis and bronchiectasis
since 1988. More recently, lung transplantation has been per-
formed for select malignant processes such as bronchioloalveolar
carcinoma (n  3) or metastatic leiomyoma (n  1).
Organ Allocation
In Canada, all lung donors located in Ontario are allocated to
Toronto. Donors from other provinces are allocated to the local
program if there is one. If there is no program, the lungs are
sequentially offered to the different lung transplant centers in the
country. Transplant physicians from the selected transplant center
then choose the recipient on the basis of blood group, size match,
patient status, and time on the waiting list.
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Our current donor management includes the administration of an
intravenous bolus of steroids (methylprednisolone 15 mg/kg) to all
potential donors immediately after the declaration of brain death.
An infusion of vasopressin (1-4 U/h) is generally used in donors
receiving inotropes to taper the requirement for epinephrine and
norepinephrine. Volume recruitment maneuvers (sighs) are per-
formed regularly to prevent atelectasis and recruit alveoli. This
maneuver is of particular importance after the apnea test, which
predisposes the lungs to atelectasis. An arterial blood gas analysis
with an FIO2 of 1.0 and a positive end-expiratory pressure of 5 cm
H2O is repeated every 2 to 3 hours, and a chest radiograph is
repeated every 3 to 4 hours. At the time of retrieval, the lungs are
re-expanded by manual inflation to exclude areas of atelectasis. A
final arterial blood gas analysis with an FIO2 of 1.0 and a positive
end-expiratory pressure of 5 cm H2O is then performed in the
operating room. The final decision regarding use of the lungs is
made based on a review of the donor history, the last arterial blood
gas tension performed after the lungs have been fully re-expanded
in the operating room, the chest radiograph appearance, broncho-
scopic findings, and direct examination and palpation of the lungs
at the time of retrieval.
Lung Preservation
The method of lung preservation has evolved from cold atelectatic
immersion in the early experience to an anterograde flush with
Euro-Collins solution in 1989. The preservation solution was then
switched from Euro-Collins to low-potassium dextran (50 mL/kg,
Perfadex, Vitrolife, Goteborg, Sweden) in April 1998, and an in
situ retrograde flush with 1 liter of Perfadex was added to the
anterograde pulmonary artery flush in July 2000. A bolus of
prostaglandin E1 (500 g, Prostin VR, Upjohn, Don Mills, On-
tario, Canada) is administered directly into the pulmonary artery
immediately before initiating the pulmonary artery flush, and 500
g of prostaglandin E1 is also added to the Perfadex solution. The
current method of lung preservation used by our group has recently
been described in detail elsewhere.7
Transplant Procedure
Single and bilateral sequential lung transplantation are performed
in a standard fashion. Single-lung transplants are generally per-
formed through a posterolateral thoracotomy. However, an antero-
lateral thoracotomy with transverse division of the sternum has
been performed occasionally in patients with emphysema requir-
ing lung-volume reduction on the contralateral side. Bilateral-lung
transplants are performed through a bilateral anterolateral thora-
cotomy in the fourth intercostal space with oblique transverse
division of the sternum. Initially, heart-lung transplants were per-
formed through a midline sternotomy, but since 1995 a bilateral
transverse thoracotomy has been used to take advantage of the
better exposure to the posterior mediastinum and both pleural
spaces. The lung with the least function, as judged by ventilation-
perfusion scan, is removed first. While the donor lung is prepared
on the back table, care is taken to preserve the collateral blood
supply to the donor bronchus from the pulmonary artery. Thus,
limited dissection of peribronchial tissue and shortening of the
bronchus up to 1 cartilage proximal to the upper lobe bronchial
takeoff are routinely used. The bronchial anastomosis is performed
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the membranous part and interrupted sutures of 4-0 Prolene (Davis
and Geck, Ontario, Canada) for the cartilaginous part. If the size
discrepancy is favorable, we prefer to telescope the recipient
bronchus into the donor bronchus. Theoretically, the recipient
bronchus may then help to maintain an adequate bronchial lumen
and act as an anastomotic stent if the donor bronchus becomes
ischemic. In pediatric recipients, we usually perform end-to-end
anastomosis with 4-0 PDS or 4-0 Vicryl (Ethicon, Markham,
Canada) for the cartilaginous part because of the smaller size of the
bronchus. In adults with small left main bronchus, an end-to-end
anastomosis is occasionally performed with interrupted 4-0 Pro-
lene. The pulmonary artery anastomosis is performed with 5-0
Prolene interrupted in 2 places, and the venous anastomosis is
performed with a horizontal everting mattress running suture to
decrease the risk of thrombogenic redundant tissue within the
lumen of the left atrium.8
At the end of the procedure, the double-lumen tube is replaced
with a single-lumen endotracheal tube, and the patient is broncho-
scoped in the operating room to remove secretions and examine
the bronchial anastomoses. Postoperatively, we routinely admin-
ister low-dose heparin (100 U/h) and Rheomacrodex (10% Dex-
tran 40, 500 mL/24 h) as an intravenous infusion for 7 days to
improve the bronchial microcirculation.
Cardiopulmonary bypass (CPB) is used only when required.
The usual indications for planned CPB are primary or secondary
pulmonary hypertension disorders. CPB is otherwise instituted
during the transplant procedure if the recipient does not tolerate
unilateral clamping of the pulmonary artery or single-lung venti-
lation. The most common time for institution of CPB is after
implantation of the first lung in a bilateral-lung transplant. Apro-
tinin has been used for all CPB procedures since 1994 to limit the
risk of postoperative bleeding.
Infection Prophylaxis
Infection prophylaxis includes the administration of broad-spec-
trum antibiotics and antiviral therapy. Antiviral therapy is directed
against cytomegalovirus (CMV). Since 1991 ganciclovir has been
administered if the donor or the recipient has positive CMV
serology. Hyperimmune globulin was also used in the highest risk
group, that is, seronegative recipients receiving lungs from a
seropositive donor. The length of time that intravenous ganciclovir
is administered has been progressively reduced during the past 10
years in recipients with positive CMV serology and is currently
limited to 2 weeks followed by oral ganciclovir for 12 weeks.
Intravenous ganciclovir is still maintained for 3 months in the
high-risk group, but the use of hyperimmune globulin has been
discontinued for the past 4 years in that group. If both donors and
recipients are seronegative, acyclovir is administered postopera-
tively as prophylaxis for Herpes simplex infections. Fungal pro-
phylaxis has been used routinely only in the past 2 years during the
in-hospital phase because of major construction occurring in our
institution.
Immunosuppression
Immunosuppression has remained similar over the years and is
based on cyclosporine, azathioprine, and corticosteroids. One dose
of oral cyclosporine (5 mg/kg) is administered preoperatively
The Journal of Thoracicimmediately before surgery. Cyclosporine is then resumed post-
operatively and administered orally or through the nasogastric tube
(5 mg/kg twice daily). Cyclosporine levels of 250 to 350 ng/mL
are targeted for the first 6 months and then tapered down. Patients
receive azathioprine immediately postoperatively orally or through
the nasogastric tube (1-2 mg/kg daily). The steroids are started
during the transplant procedure with 1 bolus (solumedrol 500 mg)
given before reperfusion of the first allograft. Then intravenous
solumedrol is started postoperatively (0.5 mg/kg daily) for 3 days
followed by oral prednisone thereafter (0.5 mg/kg daily). Induction
therapy was used for all recipients up to 1995. Thereafter, it was
discontinued, initially in recipients who tested positive for Burk-
holderia cepacia cystic fibrosis and then in everyone. Currently,
patients with a high risk of renal failure (eg, after prolonged CPB)
frequently receive 1 dose (20 mg) of basiliximab (Simulect, Nor-
vatis, Canada) on the first and fourth postoperative days to hold the
cyclosporine for up to 5 to 10 days after the transplant procedure
and to protect the kidney from cyclosporine toxicity.
Acute Rejection
The diagnosis of rejection episodes continues to be a challenge
because the clinical signs are nonspecific and resemble those of
infection, fluid overload, and ischemia-reperfusion injury. We
perform routine transbronchial biopsies at 2 and 6 weeks, 3, 6, 9,
12, 18, and 24 months. In addition, transbronchial biopsy and
bronchioloalveolar lavages are performed whenever clinically in-
dicated.
Airway Complications
All airway complications such as dehiscence, stenosis, and malacia
were recorded. Stenoses that did not require surgical interventions
were considered “mild,” whereas those requiring surgical inter-
ventions such as dilatation, stenting, or debridement were labeled
“significant.”
Statistical Analysis
Continuous variables are expressed as mean  SD or as median
and range. Statistical comparisons of categoric variables were
made by chi-square analysis or Fisher’s exact test. Statistical
comparisons of continuous variables were made by Student t test
or analysis of variance when necessary. Survival after surgery was
analyzed by the Kaplan-Meier method. The evaluation of the
differences between groups was conducted by the log-rank test.
The variables analyzed were recipient age (18 years, 18-39
years, 40-64 years, and 65 years), recipient diagnosis (cystic
fibrosis, emphysema, pulmonary fibrosis, pulmonary hypertension,
and others), time of transplant (1983-1987, 1988-1992, 1993-1997,
and 1998-2003), use of CPB (yes/no), and type of lung transplan-
tation performed (single- vs bilateral-lung transplantation). Statis-
tical analysis was performed using the GraphPad software package
(GraphPad Software, Inc, San Diego, Calif).
Results
A total of 501 recipients underwent 521 transplantations,
with 20 patients undergoing retransplantation. There were
396 bilateral sequential lung transplants, 13 en bloc double-
lung transplants, 100 single-lung transplants, and 12 heart-
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lung transplants. The number of transplants has progres-
sively increased since 1983, and since 1991, most have been
bilateral sequential lung transplants (Figure 1).
A total of 263 patients were men, and 238 patients were
women. The age of the recipients ranged from 8 to 71 years
old with a median age of 46 years. A small group of
recipients were at the extremes of age; 22 recipients were
aged less than 18 years old, and 23 recipients were aged 65
years or more.
Of single-lung transplants, 45% were performed in pa-
tients with pulmonary fibrosis and 26% were performed in
patients with emphysema. In contrast, bilateral-lung trans-
plants were performed predominantly in patients with em-








Emphysema 26 (26%) 125 (32%) 0 (0%)
Pulmonary fibrosis 45 (45%) 52 (13%) 0 (0%)
Cystic fibrosis 1 (1%) 122 (31%) 1 (8%)
Pulmonary hypertension 10 (10%) 37 (9%) 9 (75%)
Retransplantation 7 (7%) 12 (3%) 1 (8%)
Other 11 (11%) 48 (12%) 1 (8%)









Emphysema 20 (22%) 41 (40%) 34 (27%) 56 (28%)
Pulmonary fibrosis 23 (25%) 9 (9%) 19 (16%) 46 (23%)
Cystic fibrosis 18 (19%) 25 (25%) 34 (27%) 47 (23%)
Pulmonary hypertension 10 (11%) 10 (10%) 15 (12%) 21 (10%)
Retransplantation 8 (9%) 2 (2%) 4 (3%) 6 (3%)
Other 14 (14%) 15 (14%) 18 (15%) 26 (13%)
Figure 1. Number and type of transplant performed b
transplant; DLTx, double-lung transplant; BLTx, bilaterphysema (32%) and cystic fibrosis (31%), and less fre-
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Lung transplantation was performed in 56 patients with
pulmonary hypertension. The majority of them underwent
bilateral-lung transplantation (n  37), 10 underwent sin-
gle-lung transplantation, and 9 underwent heart-lung trans-
plantation. Lung retransplantations were bilateral in 12 pa-
tients, limited to 1 side in 7 patients, and combined heart
and lung in 1 patient.
The proportion of patients with emphysema, pulmonary
fibrosis, cystic fibrosis, and pulmonary hypertension has not
changed greatly over time despite a transient increase in the
proportion of patients with emphysema in the early 1990s
(Table 2). The proportion of lung retransplantations per-
formed decreased from 9% before 1991 to 3% or less
thereafter. We currently perform lung retransplantation pri-
marily in patients with chronic graft dysfunction. In the
early experience, lung retransplantation was also performed
in patients with primary graft failure, but 3 of 4 patients
undergoing retransplantation because of primary graft dys-
function died within 2 months of surgery, and therefore this
indication was abandoned.
Overall, CPB was used in 35% of the patients who have
undergone lung transplantation since 1991. CPB was used
in essentially all patients with a diagnosis of primary pul-
monary hypertension. However, CPB was used in 49% of
patients with pulmonary fibrosis, in 26% of patients with
cystic fibrosis, and in only 13% of patients with emphysema
(Figure 2).
The proportion of patients experiencing airway compli-
cations decreased from 27% between 1983 and 1990 to 13%
between 1991 and 1994, and to 9% between 1999 and 2003
(Figure 3). During the last 4 years, only 20 of 371 bronchial
anastomoses (5.4%) presented with some degree of bron-
chial complications. Significant stenoses occurred in 11
cases and required serial dilatation (n  6) and stent place-
ar at the Toronto General Hospital. HLTx, Heart-lung
ng transplant; SLTx, single-lung transplant.y yement (n  5). Debridement for excessive granulation tissue
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cases on flexible bronchoscopy, but both patients were
clinically asymptomatic and did not require any treatment.
Bronchomalacia was observed in 2 cases, and bronchial
dehiscence occurred in 4 cases. Two dehiscences were
partial and healed after conservative management. One de-
hiscence was located along the membranous part of the
bronchus and was successfully treated with adequate per-
cutaneous drainage, and 1 dehiscence occurred in a patient
presenting with cardiac dysfunction after bilateral-lung
transplantation. This patient eventually died in the postop-
erative course.
The overall 5-, 10-, and 15-year survivals for the entire
cohort of patients were 55.1% (95% confidence interval:
5%), 35.3% (6%), and 26.5% (11%), respectively
(Figure 4). The best survival was achieved in recipients with
primary pulmonary hypertension and in recipients with cys-
tic fibrosis who tested negative for Burkholderia (B) cepa-
cia before the transplant procedure. The recipient group
with B cepacia negative cystic fibrosis had 5- and 10-year
survivals of 76% and 52%, respectively. Patients with pri-
mary pulmonary hypertension achieved better long-term
survival than patients with Eisenmenger syndrome or pul-
monary fibrosis, with a 10-year survival of 59% versus 38%
and 24%, respectively (Figure 4). The worst survival was
observed in recipients with cystic fibrosis who tested posi-
tive for B cepacia before the transplant procedure, with a
survival of only 15% at 10 years (Figure 4). However, the
difference in the long-term survival between recipients who
tested positive for B cepacia and negative for cystic fibrosis
was mainly because of the high rate of septic complications
in the B cepacia positive group during the first 6 months
after transplantation. Indeed, 15 of 46 recipients died during
the first 6 postoperative months in the B cepacia positive
group, and all deaths were attributable to B cepacia sepsis.
In contrast, only 3 of 78 recipients died of sepsis during the
same postoperative period in the B cepacia negative group.
Figure 2. Proportion of transplantations performed with
cystic fibrosis.After more than 6 months of follow-up, the causes of death
The Journal of Thoracicwere similar between the B cepacia positive and negative
groups, and the survival curves remained parallel.
As a result of the high rate of posttransplant infections in
the B cepacia positive group, the immunosuppressive regi-
men has been reduced and the infection prophylaxis has
been enhanced. Since 1995, we have aimed for cyclosporine
levels of 250 to 300 g/mL instead of 250 to 350 g/mL for
the first 6 postoperative months, and azathioprine has been
given at a dose of 1 mg · kg · d instead of 1.5 to 2.0 mg · kg
· d. Antimicrobial therapy has been extended from 2 to 4
antibiotics including ceftazidime, chloramphenicol, tobra-
mycin, and trimethoprim-sulfamethoxazole. We have also
added an aggressive intraoperative irrigation of the airway
with a dilute Betadine solution before implantation of the
allograft since 1999. We believe that these interventions
have improved the outcome in this challenging group of
patients and led to a reduction in the number of deaths
caused by B cepacia infection to only 2 of 10 patients who
underwent transplantation during the past 4 years.
Among patients undergoing bilateral-lung transplanta-
tion for emphysema, the long-term survival was signifi-
cantly worse in those with alpha-1 antitrypsin deficiency
than in those with chronic obstructive pulmonary disease
Figure 3. Proportion of patients with airway anastomotic compli-
cations decreased over time.
since 1991. PPH, Primary pulmonary hypertension; CF,CPB(COPD) without the genetic deficiency (Figure 4). The
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10-year survival was 23% in recipients with alpha-1 anti-
trypsin deficiency, whereas it was 43% in the remaining
recipients with emphysema (P  .04).
Recipient age and use of CPB had no significant impact
on the long-term outcome of patients after lung transplan-
tation. The effect of time of transplant also had no signifi-
cant impact on long-term outcome. The long-term survival
tended to be better in patients undergoing bilateral-lung
transplants than in patients undergoing single-lung trans-
plants (P .07). However, this effect disappeared when the
type of transplant was analyzed separately for emphysema,
pulmonary fibrosis, pulmonary hypertension, and other
types of parenchymal diseases.
TABLE 3. Causes of death in 235 of the 501 recipients who
underwent transplantation
Sepsis 82 (35%)
Chronic graft failure 68 (29%)
Malignancy 21 (9%)
Cardiac event 15 (6%)
Primary graft failure 12 (4%)
Pulmonary emboli 5 (2%)
Other 32 (15%)
Figure 4. A, Overall survival for 501 recipients (dashed
with cystic fibrosis was significantly better in those wh
who tested positive for B cepacia. C, Survival was sig
bilateral-lung transplantation for COPD than for reci
recipients undergoing lung transplantation for primary
Eisenmenger syndrome (severe pulmonary hypertension
PPH, primary pulmonary hypertension; SPH, severe pul
disease; AAT, alpha-1 antitrypsin.The causes of death are summarized in Table 3. Malig-
1498 The Journal of Thoracic and Cardiovascular Surgery ● Manancy included mainly lymphoma (n  10) and less fre-
quently solid-organ tumors such as lung carcinoma (n  3),
liver carcinoma (n  2), and colon, breast, esophagus, and
renal carcinomas (n  1 each). Skin tumors were the cause
of death in 2 recipients.
Sepsis was the main cause of death during the first 6
months after transplantation; chronic graft failure and bron-
chiolitis obliterans syndrome (BOS) became the predomi-
nant causes of death thereafter (Table 4). Despite the risk of
sepsis in the group with B cepacia positive cystic fibrosis
during the first 6 months after transplant, the rate of death
from BOS is high in those surviving more than 6 months
(56%) and not significantly different from recipients with B
cepacia negative cystic fibrosis (60%). The susceptibility to
septic complications seems to differ in recipients with em-
physema according to whether they are alpha-1 antitrypsin
deficient or not. Indeed, 4 of 88 patients who underwent
transplantation for COPD died during the first 6 months
after transplantation, and only 1 of them died of sepsis. In
contrast, 16 of 63 patients with alpha-1 antitrypsin defi-
ciency died within 6 months of surgery, and 8 of them died
of sepsis. It is interesting that beyond 6 months, patients
with alpha-1 antitrypsin deficiency still exhibited a high
susceptibility to septic complications (45% of the deaths
s: 95% confidence intervals). B, Survival for recipients
ted negative for B cepacia when compared with those
ntly better in recipients with emphysema undergoing
s with alpha-1 antitrypsin deficiency. D, Survival in
onary hypertension was better than for recipients with
pulmonary fibrosis. CF, Cystic fibrosis; B, Burkholderia;
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The rate of septic complications in the alpha-1 antitryp-
sin group was not related to the occurrence of BOS. Indeed,
the incidence of BOS in patients surviving more than 6
months was not significantly different between those who
tested negative (37%) or positive (56%) for B cepacia cystic
fibrosis, or among those who had primary pulmonary hy-
pertension (44%), COPD (39%), alpha-1 antitrypsin defi-
ciency (46%), or pulmonary fibrosis (25%). Thus, the inci-
dence of BOS in recipients deficient in alpha-1 antitrypsin
was similar to other groups, but the proportion of deaths
from BOS was smaller because there were more septic
deaths (Table 4). Among all patients surviving more than 6
months, 11% (5/47) died of BOS in the alpha-1 antitrypsin
deficient group versus 18% (65/365) in the remaining re-
cipient groups (P .2). However, 21% (10/47) of recipients
with alpha-1 antitrypsin deficiency died of late sepsis versus
only 6% (21/365) in the remaining recipients (P  .0001).
Discussion
The Toronto Lung Transplant Program was started in the
1970s. After several years of research, the first successful
single-lung transplant was performed in 1983 in a patient
with pulmonary fibrosis. That patient eventually died 7
years later of BOS and renal failure. In 1986, the first
double-lung transplant was performed in a patient with
emphysema secondary to alpha-1 antitrypsin deficiency.
The patient remained well and active for 15 years after the
transplant before dying suddenly of a subarachnoid hemor-
rhage.
After this initial development, lung transplantation has
had increasing success and become the mainstay of therapy
for many end-stage pulmonary diseases worldwide. The
indications have been extended from patients with pulmo-
nary fibrosis and obstructive lung disease to patients with
infectious processes and pulmonary hypertension. Recipient
selection has also been extended to selected higher risk
recipients, such as patients who are ventilator-dependent or
who have end-stage lung disease associated with other
chronic diseases (including coronary artery disease and liver
dysfunction). The age limit has also progressively been
extended to patients 65 years of age and older.
Our program favors the use of bilateral-lung transplan-
tation. The international experience and specific reports
from large centers have suggested that long-term survival is
significantly better in emphysematous recipients undergoing
bilateral-lung transplant rather than single-lung trans-
plant.9,10 In addition, we find recipients of bilateral-lung
transplants to be easier to manage during the postoperative
period if prolonged mechanical ventilation is required. Sin-
gle-lung transplantation is generally performed when only 1
lung is available because the other lung is either used by
The Journal of Thoracicanother program or is compromised because of localized
trauma or infection. Our preference for bilateral-lung trans-
plantation, even for patients with COPD, may explain the
good long-term outcome observed for these patients in our
series (10-year survival of 43%).
The overall 10-year survival is 35% in our series. How-
ever, some groups of recipients achieved better long-term
survival. For instance, the 10-year survival was more than
50% for recipients with primary pulmonary hypertension
and B cepacia negative cystic fibrosis, whereas it was only
24% for recipients with pulmonary fibrosis. Although sev-
TABLE 4. Causes of death according to recipient lung
disease and time after transplant
Time after transplant
<6 mo >6 mo
Pulmonary fibrosis (n  97)
Total number of deaths 22 29
Death from BOS 1 (5%) 13 (45%)
Death from sepsis 11 (50%) 4 (14%)
Death from other causes 10 (45%) 12 (41%)
COPD (n  88)
Total number of deaths 4 29
Death from BOS 0 (0%) 16 (55%)
Death from sepsis 1 (25%) 4 (14%)
Death from other causes 3 (75%) 9 (31%)
Alpha-1 antitrypsin deficiency (n
 63)
Total number of deaths 16 22
Death from BOS 0 (0%) 5 (23%)
Death from sepsis 8 (50%) 10 (45%)
Death from other causes 8 (50%) 7 (32%)
Pulmonary hypertension (n  52)
Total number of deaths 17 11
Death from BOS 1 (6%) 7 (64%)
Death from sepsis 8 (47%) 0 (0%)
Death from other causes 8 (47%) 4 (36%)
Cystic fibrosis, B cepacia
negative (n  78)
Total number of deaths 6 15
Death from BOS 0 (0%) 9 (60%)
Death from sepsis 3 (50%) 3 (20%)
Death from other causes 3 (50%) 3 (20%)
Cystic fibrosis, B cepacia
positive (n  46)
Total number of deaths 15 16
Death from BOS 0 (0%) 9 (56%)
Death from sepsis 15 (100%) 4 (25%)
Death from other causes 0 (0%) 3 (19%)
Other causes of end-stage lung
disease (n  77)
Total number of deaths 9 24
Death from BOS 0 (0%) 11 (46%)
Death from sepsis 5 (55%) 6 (25%)
Death from other causes 4 (45%) 7 (29%)
BOS, Bronchiolitis obliterans syndrome; COPD, chronic obstructive pulmo-
nary disease.eral groups have reported excellent results in recipients with
and Cardiovascular Surgery ● Volume 127, Number 5 1499
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recipients, very few have reported a long-term survival
more than 50% for recipients with primary pulmonary hy-
pertension.11-13 The reason for this good long-term outcome
remains speculative. One reason may relate to the quality of
the lung donor used. Indeed, recipients with primary pul-
monary hypertension have an increased risk of postopera-
tive complications, and extended or marginal donors are less
frequently used for this group of recipients. We and others
have also observed that the pathologic lesions leading to
primary pulmonary hypertension can regress after single-
lung transplantation because of preferential blood flow to
the transplanted lung and hemodynamic unloading of the
native lung.14,15 Thus, when the transplanted lung progres-
sively fails, the native lung may be able to resume some
lung function and keep the recipient alive.
In our experience with 501 patients, the majority died of
sepsis (35%) and chronic graft failure (29%). However, the
cause of death varied with time after transplant. Overall,
sepsis was the predominant cause of death in the first 6
months after the transplant procedure, whereas chronic graft
failure was the main cause of death after 6 months. The only
exception was patients with a preoperative diagnosis of
alpha-1 antitrypsin deficiency who continued to be predis-
posed to sepsis-related mortality, even beyond 6 months
after transplant. Sepsis was predominantly caused by bac-
terial infection both from pulmonary and extra pulmonary
origin. Of note, in the alpha-1 antitrypsin group, 25% of
patients had an episode of sepsis of abdominal origin while
followed by the lung transplant team, and in 17% of them it
contributed to their deaths. In contrast, in the remaining
patients with emphysema, who were not alpha-1 antitrypsin
deficient, abdominal sepsis occurred in only 8% of patients
and contributed to only 1% of deaths.
Patients with alpha-1 antitrypsin deficiency also had a
higher early postoperative mortality rate and a shorter long-
term survival than recipients with emphysema without al-
pha-1 antitrypsin deficiency. This finding has not been re-
ported and may be the result of an increased level of
interleukin-8 and increased chemotactic activity of neutro-
phils in the lung tissue of patients with alpha-1 antitrypsin
deficiency.16 Both interleukin-8 and neutrophil activation
have been shown to be associated with an increased risk of
acute graft dysfunction after lung transplantation.17,18 In
addition, lung transplant recipients deficient in alpha-1 an-
titrypsin have been shown to have lower levels of antipro-
tease defenses during reperfusion injury, acute rejection,
and infection, and the difficulty in clearing up neutrophils
from the lung parenchyma may eventually be associated
with increased mortality in the long term.19
Conclusion
Lung transplantation offers long-term survival in many pa-
tients with end-stage lung disease. The long-term survival
1500 The Journal of Thoracic and Cardiovascular Surgery ● Mawas best in patients who underwent transplantation for
primary pulmonary hypertension and cystic fibrosis (B ce-
pacia negative), with a 10-year survival greater than 50%.
The lowest survivals were observed in recipients with pul-
monary fibrosis, alpha-1 antitrypsin deficiency, and B cepa-
cia positive cystic fibrosis, with 10-year survivals of 24%,
23%, and 15%, respectively, after the transplant procedure.
The primary cause of death was sepsis during the initial 6
months after surgery and chronic graft dysfunction later on.
Sepsis, however, remained an important cause of death in
patients with alpha-1 antitrypsin deficiency even beyond 6
months after transplantation. Challenges for the future will
be to reduce the incidence of infection and to prevent the
development of chronic graft dysfunction or obliterative
bronchiolitis.
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Discussion
Dr Thomas M. Egan (Chapel Hill, NC). In many respects your
results agree with those of the larger International Society for
Heart and Lung Transplantation (ISHLT) data set. It is discourag-
ing that a 70 year old with stage I lung cancer has a better
prognosis today than a 25 year old undergoing a lung transplant
despite 20 years of experience. It is also discouraging that there are
not nearly enough lungs to go around to treat everyone with
end-stage lung disease.
In your series, the 2 main causes of death were sepsis related to
broad, nonspecific immunosuppression and BOS, an inevitable
process that we do not seem to understand. Your observation that
patients with pulmonary hypertension have a poor earlier progno-
sis is corroborated by the ISHLT registry. This registry also
confirms your observation that patients with alpha-1 antitrypsin
deficiency do not do as well early, but in the ISHLT registry they
have a better long-term survival than older patients with COPD,
unlike in your series.
I have a few questions. With the 521 transplants that you have
performed, have you had the opportunity to perform any univariate
or multivariate analyses to identify risk factors for death? Can you
explain why your patients with COPD had a 5-year survival that
was not so good, almost 20% better than reported in the ISHLT
registry or south of the border? Could it be the colder Canadian
air? How many patients died while on your waiting list during this
interval? And can you clarify for us the criteria for distribution of
lungs in Canada? The United Network for Organ Sharing is
currently struggling to devise an organ distribution algorithm in
the United States that places less emphasis on time waiting and
more emphasis on severity of illness. How do you determine who
is offered a lung when lungs become available?
Finally, I applaud your group’s long tradition of taking clinical
problems to the laboratory to come up with solutions. I would
submit that there are 3 challenges for future lung transplant sur-
geons: the shortage of suitable lungs; potent, nonspecific immu-
nosuppression that causes infection; and the scourge of BOS. So
my last question is, from your perspective of the last 20 years, how
do you see us finding solutions to these issues in the next 20 years?
The Journal of ThoracicDr de Perrot. We have not yet performed multivariate analy-
ses, but we are still retrieving some of the data for other variables,
such as CMV and donor factors for each of the recipients.
The survival in the COPD group is surprisingly good. How-
ever, the reason is not very clear. One of them could be the long
tradition of transplantation in Toronto, which may explain some of
those results.
An unexpected finding comes from the differences between the
groups with COPD and alpha-1 antitrypsin deficiency. The group
with alpha-1 antitrypsin deficiency did worse during the earlier
postoperative period and later on as well. Despite the fact that the
operation is relatively similar, there may be some reasons associ-
ated with the alpha-1 antitrypsin deficiency that may explain these
findings.
The number of patients who die while on the waiting list is low.
Our current waiting time is approximately 3 to 4 months. During
the last few years, we have expanded the number of donors used.
Earlier on, 10 years ago, approximately 15% to 20% of the lung
donors were used, and this has increased to 40% last year. So the
fact that we have been more aggressive with these donors has
decreased the waiting time, and it has certainly helped to decrease
the number of deaths on the waiting list.
The criteria for donor lung distribution in Canada is, as you
know, different from the United States. The donors are attributed
alternatively to each center, and the center determines who should
receive the organ. Certainly the sickness of each patient is taken
into consideration to determine which recipient should get the
lungs. This may also affect the number of deaths on the waiting
list.
The focus for the next decade or 2 certainly will be on the
relatively poor long-term survival. The first 10 years of successful
lung transplantation focused on technical issues, and the last 10
years were associated with improvement in the methods of lung
preservation. So possibly in the next decade we will see improve-
ment in the prevention and treatment of BOS.
Dr Si M. Pham (Miami, Fla). During the last 20 years, there
have been quite a few changes in the use of immunosuppressive
agents. The 2 major complications you report, infection and
chronic rejection, can be partially attributed to the immunosup-
pression protocol used. Has the immunosuppression protocol at
your center changed during the last 20 years?
Dr de Perrot. It certainly has. Whereas initially most of these
patients received induction therapy, no systematic induction ther-
apy has been used in the past 6 to 8 years in Toronto. I think that
the most significant change has occurred in the patients who test
positive for B cepacia cystic fibrosis. These patients have had
lower immunosuppression for the last several years and received
broad-spectrum antibiotics. This was associated with tracheal
washing during the surgery. These changes were associated with
an improvement in the number of deaths resulting from sepsis,
which decreased from approximately 40% in the early period to
approximately 20% in the past 4 years or so for the B cepacia
group.
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